Not exclusively tissue factor: Neutrophil extracellular traps provide another link between chemotherapy and thrombosis

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 11, 2011, Pages 2311-2312

  Van Den Berg, Y W ^a   Reitsma, P H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED DNA; THROMBIN ANTITHROMBIN COMPLEX; THROMBOPLASTIN;

CANCER CHEMOTHERAPY; CELL FREE SYSTEM; EXTRACELLULAR MATRIX; HEMOSTASIS; HUMAN; NEUTROPHIL; NEUTROPHIL EXTRACELLULAR TRAP; NONHUMAN; NOTE; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; VEIN THROMBOSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DNA; DOXORUBICIN; ENDOTHELIAL CELLS; EPIRUBICIN; FEMALE; HISTONES; HUMANS; MONOCYTES; NEOPLASMS; PROTEIN C; THROMBIN; THROMBOMODULIN; THROMBOPHILIA; THROMBOPLASTIN; THROMBOSIS;

EID: 80055101700     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04502.x     Document Type: Note

References (15)

1. Piccioli A, Falanga A, Baccaglini U, Marchetti M, Prandoni P. Cancer and venous thromboembolism. Semin Thromb Hemost 2006; 32: 694-9.
2. Ruf W, Disse J, Carneiro-Lobo TC, Yokota N, Schaffner F. Tissue factor and cell signalling in cancer progression and thrombosis. J Thromb Haemost 2011; 9 (Suppl. 1): 306-15.
3. Owens AP III, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res 2011; 108: 1284-97.
4. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-22.
5. Heit JA. Risk factors for venous thromboembolism. Clin Chest Med 2003; 24: 1-12.
6. Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, De Pauw S. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988; 318: 404-7.
7. King PD, Perry MC. Hepatotoxicity of chemotherapy. Oncologist 2001; 6: 162-76.
8. Swystun LL, Shin LY, Beaudin S, Liaw PC. Chemotherapeutic agents doxorubicin and epirubicin induce a procoagulant phenotype on endothelial cells and blood monocytes. J Thromb Haemost 2009; 7: 619-26.
9. Boles JC, Williams JC, Hollingsworth RM, Wang JG, Glover SL, Owens AP III, Barcel DA, Kasthuri RS, Key NS, Mackman N. Anthracycline treatment of the human monocytic leukemia cell line THP-1 increases phosphatidylserine exposure and tissue factor activity. Thromb Res 2011; doi:10.1016/j.thrombres.2011.06.022.
10. Mukherjee SD, Swystun LL, Mackman N, Wang JG, Pond G, Levine MN, Liaw PC. Impact of chemotherapy on thrombin generation and on the protein C pathway in breast cancer patients. Pathophysiol Haemost Thromb 2010; 37: 88-97.
11. Kirwan CC, McDowell G, McCollum CN, Kumar S, Byrne GJ. Early changes in the haemostatic and procoagulant systems after chemotherapy for breast cancer. Br J Cancer 2008; 99: 1000-6.
12. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11: 426-37.
13. Swystun LL, Mukherjee S, Liaw PC. Breast cancer chemotherapy induces the release of cell free DNA, a novel procoagulant stimulus. J Thromb Haemost 2011; 9: 2313-21.
14. Maas C, Oschatz C, Renne T. The plasma contact system 2.0. Semin Thromb Hemost 2011; 37: 375-81.
15. Borissoff JI, ten Cate H. From neutrophil extracellular traps (NETs) release to thrombosis: an overshooting host-defense mechanism? J Thromb Haemost 2011; 9: 1791-4.